Publication details
The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents
| Authors | |
|---|---|
| Year of publication | 2019 |
| Type | Article in Periodical |
| Magazine / Source | Anticancer Research |
| MU Faculty or unit | |
| Citation | |
| web | http://dx.doi.org/10.21873/anticanres.13761 |
| Doi | http://dx.doi.org/10.21873/anticanres.13761 |
| Keywords | Primary tumour sidedness; colorectal cancer; cetuximab; panitumumab; bevacizumab |
| Description | Background/Aim: The aim of our study was to assess the predictive role of primary tumour sidedness (PTS) in patients with metastatic colorectal cancer (mCRC) harbouring wild-type RAS and treated with targeted agents. Patients and Methods: The cohort included 178 patients treated with first-line chemotherapy plus cetuximab, panitumumab or bevacizumab. Results: We observed longer progression-free survival (PFS) and overall survival (OS) in patients with left-sided (L-CRC) compared to right-sided tumours (R-CRC) treated with anti-EGFR mAbs (p=0.0033 and p=0.0037), while there was no difference in patients treated with bevacizumab (p=0.076 and p=0.56). Finally, we observed longer PFS and OS in patients with L-CRC treated with anti-EGFR mAbs and those with R-CRC treated with bevacizumab compared to the reverse combination (p=0.0002 and p=0.011). Conclusion: PTS is a predictive factor for anti-EGFR mAbs, not for bevacizumab. Superior survival was observed when anti-EGFR mAbs were used for L-CRC and bevacizumab for R-CRC. |